115 related articles for article (PubMed ID: 33174734)
21. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
Mehta M; Basalingappa K; Griffith JN; Andrade D; Babu A; Amreddy N; Muralidharan R; Gorospe M; Herman T; Ding WQ; Ramesh R; Munshi A
Oncotarget; 2016 Oct; 7(40):64820-64835. PubMed ID: 27588488
[TBL] [Abstract][Full Text] [Related]
22. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
[TBL] [Abstract][Full Text] [Related]
23. [Antiangiogenic drugs enhance the ability of invasion and metastasis of breast cancer cells under serum starvation and hypoxia].
Wei L; Cuicui Z; Jing W; Kai L
Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):244-50. PubMed ID: 26462887
[TBL] [Abstract][Full Text] [Related]
24. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
25. Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Tilli TM; Carels N; Tuszynski JA; Pasdar M
Oncotarget; 2016 Sep; 7(39):63189-63203. PubMed ID: 27527857
[TBL] [Abstract][Full Text] [Related]
26. Use of Labelled tLyP-1 as a Novel Ligand Targeting the NRP Receptor to Image Glioma.
Wu HB; Wang Z; Wang QS; Han YJ; Wang M; Zhou WL; Li HS
PLoS One; 2015; 10(9):e0137676. PubMed ID: 26398657
[TBL] [Abstract][Full Text] [Related]
27. Unusual roles of caspase-8 in triple-negative breast cancer cell line MDA-MB-231.
De Blasio A; Di Fiore R; Morreale M; Carlisi D; Drago-Ferrante R; Montalbano M; Scerri C; Tesoriere G; Vento R
Int J Oncol; 2016 Jun; 48(6):2339-48. PubMed ID: 27082853
[TBL] [Abstract][Full Text] [Related]
28. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
Wu C; Qiu S; Liu P; Ge Y; Gao X
J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
[TBL] [Abstract][Full Text] [Related]
29. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
[TBL] [Abstract][Full Text] [Related]
30. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
31. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
[TBL] [Abstract][Full Text] [Related]
32. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
33. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
34. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
35. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
[TBL] [Abstract][Full Text] [Related]
37. Proliferation-associated long noncoding RNA, TMPO-AS1, is a potential therapeutic target for triple-negative breast cancer.
Mitobe Y; Ikeda K; Sato W; Kodama Y; Naito M; Gotoh N; Miyata K; Kataoka K; Sasaki H; Horie-Inoue K; Inoue S
Cancer Sci; 2020 Jul; 111(7):2440-2450. PubMed ID: 32437068
[TBL] [Abstract][Full Text] [Related]
38. Long non-coding RNA PCAT29 regulates the growth, migration and invasion of human triple-negative breast cancer cells.
Lu C; Li HL; Zhang X; Zhao J; Zheng WH
J BUON; 2020; 25(2):621-626. PubMed ID: 32521844
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
Jin K; Pandey NB; Popel AS
Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]